Alto Neuroscience, Inc. (ANRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 4:15 PM ET
Alto Neuroscience, Inc. (ANRO) Statistics
Alto Neuroscience (ANRO) has a market cap of $1.09B and an enterprise value of $784.44M. Its share count is up 71.68% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 27.89% below the market cap, as cash exceeds debt.
| Market Cap | $1.09B |
|---|---|
| Enterprise Value | $784.44M |
| Latest price (Nov 17, 2026) | $24.92 |
Key Dates
| Last Earnings Date | Nov 10, 2026 |
|---|---|
| Fiscal Year End | September |
Price Statistics
The stock is up 105.78% over 52 weeks and trades 4.08% below its 50-day average.
| Beta (1Y) | 1.78 |
|---|---|
| 52-Week Change | +105.78% |
| 1-Month Change | +9.20% |
| 3-Month Change | -28.58% |
| 6-Month Change | +21.86% |
| Total Return (1Y) | +105.78% |
| Return vs SPY (1Y) | +57.39% |
| Max Drawdown (1Y) | -40.75% |
| Max Drawdown (3Y) | -91.74% |
| Sharpe Ratio (1Y) | 0.72 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $25.98 |
| 200-Day Average | $24.84 |
| 52-Week Range | $12.51 to $37.48 |
| RSI (14 Days) | 47.3 |
| Average Volume (20 Days) | 597.64K |
Financial Position
Current assets cover 18.12x current liabilities, and total debt is 0.05x shareholder equity.
| Current Ratio | 18.12x |
|---|---|
| Quick Ratio | 18.12x |
| Debt / Equity | 0.05x |
| Interest Coverage | -44.89x |
Returns and Efficiency
Return on invested capital is -23.54% over the last 12 months, against a 5-year average of 25.25%.
| Return on Equity (ROE) | -32.10% |
|---|---|
| Return on Assets (ROA) | -29.15% |
| Return on Invested Capital (ROIC) | -23.54% |
| Return on Capital Employed (ROCE) | -30.16% |
| ROA (5Y Average) | -39.43% |
| ROIC (5Y Average) | 25.25% |
Scores
ANRO has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | $32.18M |
| Pretax Income | -$95.18M |
| Net Income | -$95.18M |
| EBIT | -$93.11M |
| Reported EPS (TTM) | -$2.44 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.82% of the $326.50M in total assets.
| Cash and Equivalents | $319.34M |
|---|---|
| Total Debt | $15.98M |
| Net Cash | $303.36M |
| Net Cash Per Share | $6.52 |
| Working Capital | $305.36M |
| Shareholder Equity | $296.53M |
| Book Value Per Share | $6.37 |
| Total Assets | $326.50M |
| Total Liabilities | $29.98M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $556.00K of capital spending, operating cash flow left -$79.68M of free cash flow.
| Operating Cash Flow | -$79.12M |
|---|---|
| Capital Expenditures | $556.00K |
| Free Cash Flow | -$79.68M |
| FCF Per Share | -$1.99 |
| Depreciation and Amortization | $1.74M |
Trailing 12 months through Sep 30, 2026.
Peer Position
Against 6 similar companies, ANRO has the 4th highest ROIC.
ROICPeer median -42.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -16.64%
| ROIC | -23.54% vs -42.31% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -16.64% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ANRO
What is ANRO's market cap?
Alto Neuroscience has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $784.44M.
How many shares of ANRO are outstanding?
Alto Neuroscience has 46.53M shares outstanding. The count is up 71.68% from a year earlier.
Does ANRO pay a dividend?
No. Alto Neuroscience does not pay a dividend.
How much debt does ANRO have?
Alto Neuroscience has $15.98M of total debt and $319.34M of cash and equivalents, a net cash position of $303.36M.
ANRO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors